CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SARS-CoV-2 convalescent plasma treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug659 Convalescent plasma (CP) Wiki 1.00
drug2314 Standard care Wiki 0.38

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19: A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma)

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global population with significant morbidity and mortality. One of the main concerns is the management of the patients since there is no specific treatment for this condition. Therefore, in SARS-CoV-2 patients the compassionate use of off-label therapies has been initiated; such as the use of plasma from convalescent patients. This treatment has been used in other pandemics like SARS-CoV-1, H5N1, H1N1, Ebola, among others. This study is a phase II/III randomized clinical trial to assess the effectiveness and safety of convalescent plasma administration in patients with high-risk SARS-CoV-2.

NCT04425837 Sars-CoV2 Covid-19 Biological: SARS-CoV-2 convalescent plasma treatment Other: Standard care

Primary Outcomes

Description: Death of the patient (yes/no)

Measure: Mortality

Time: Up to 30 days after the study enrollment

Description: Presence of any of the following adverse events (yes/no): Nonhemolytic febrile reactions Allergic reactions Acute hemolytic reactions Non-immune hemolysis Acute transfusion-related lung damage Transfusion-related circulatory overload Metabolic reactions Hypotensive reactions Delayed hemolytic reactions Post transfusion purple Graft versus host disease Bacterial contamination of blood components Viral infections Other infections (syphilis, prions, malaria, Chagas, yellow fever, dengue)

Measure: Adverse events

Time: Up to 30 days after the study enrollment

Description: Admitted to intensive care units (ICUs) (yes/no)

Measure: ICU admission

Time: Up to 30 days after the study enrollment

Description: Mechanical ventilation requirement (yes/no)

Measure: Mechanical ventilation

Time: Up to 30 days after the study enrollment

Secondary Outcomes

Description: Intensive care unit length of stay

Measure: ICU length

Time: Up to 30 days after the study enrollment

Description: D dimer reduction below 1mcg / ml

Measure: Reduction of D Dimer

Time: Assessment at day 30 after study enrollment

Description: Reduction of LDH below 350 IU / L

Measure: LDH reduction

Time: Assessment at day 30 after study enrollment

Description: Reduction of troponin level to than 8 pg / mL

Measure: Reduction of Troponin level

Time: Assessment at day 30 after study enrollment

Description: Decrease in ferritin level below 1025 mcg / L

Measure: Decrease in ferritin level

Time: Assessment at day 30 after study enrollment

Description: Decrease in procalcitonin level below 0.1ng / ml

Measure: Decrease in procalcitonin level

Time: Assessment at day 30 after study enrollment

Description: Decrease in CRP level bellow <8 mg / L

Measure: Decrease in CRP

Time: Assessment at day 30 after study enrollment

Description: Increase in lymphocyte count greater than 0.6 x 10-9 / L

Measure: Increase in lymphocyte count

Time: Assessment at day 30 after study enrollment

Description: Increase in PaO2 / Fio2 greater than 200

Measure: Increase in PaO2 / Fio2

Time: Assessment at day 30 after study enrollment

Description: Scale of 24 points, greater number indicates worst outcome

Measure: Decrease in Sequential Organ failure assessment (SOFA ) score

Time: Assessment at day 30 after study enrollment

Description: Extracorporeal membrane oxygenation requirement (ECMO)

Measure: Extracorporeal membrane oxygenation (ECMO)

Time: Assessment at day 30 after study enrollment

Description: Decrease in the percentage of lung infiltration

Measure: Lung infiltration

Time: Assessment at day 30 after study enrollment

No related HPO nodes (Using clinical trials)